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Abstract
Introduction—Our objective was to determine effects of zoledronic acid (ZA) on atrial 
electrophysiological parameters and electrocardiographic measurements.
Methods and Results—Ex vivo perfusion study: Isolated guinea pig hearts were perfused with 
modified Krebs-Henseleit (K-H) buffer with or without ZA 0.07 mg/kg/L (each n=6). In ZA-
perfused hearts, atrial action potential at 90% repolarization (APD90) decreased more from 
baseline than in controls (−23.2% ± −5.1% vs −2.1% ± −8.1%, p<0.0001), as did APD30 (−28.8% 
± −3.8% vs −2.1% ± −2.1%, p<0.0001). In vivo dose-response study: Guinea pigs underwent 
intraperitoneal injections every two weeks in one of 4 groups (each n=8): ZA 0.007 mg/kg (low-
dose), ZA 0.07 mg/kg (medium-dose), ZA 0.7 mg/kg (high-dose) or placebo. Hearts were excised 
at 8 weeks and perfused with modified K-H. Atrial effective refractory period (ERP) was lower 
with medium and high-dose ZA versus placebo (p=0.004). Atrial APD30 was lower with high-
dose ZA versus placebo, low and medium doses (p<0.001). Canine ECG study: Mature female 
beagles received intravenous ZA 0.067 mg/kg or saline (placebo) (each n=6) every two weeks for 
12 weeks. P wave dispersion was greater in the ZA group (7.7±3.7 vs. 3.4±2.6 ms, p=0.04). There 
were no significant differences in P wave index, maximum or minimum P wave duration, or PR 
interval.
Conclusion—ZA shortens left atrial APD and ERP and increases P wave dispersion.
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Introduction
Osteoporosis occurs in ~ 50% of women and ~ 20% of men over the age of 50,1 and is 
associated with a high incidence of fractures. Bisphosphonate drugs reduce the risk of 
fractures in patients with osteoporosis,2 and have become the gold standard for treatment. 
Bisphosphonates are also recommended for bone pain and fracture prevention in patients 
with metastatic cancer,3 and are increasingly used in this patient population. In addition, 
bisphosphonate drugs are used for improvement in bone mineral density in patients with 
primary hyperparathyroidism,4 reduction in bone turnover in patients with Paget’s disease,5 
prevention and treatment of glucocorticoid-induced osteoporosis,6 and hypercalcemia of 
malignancy.7 Numerous bisphosphonates are available, including alendronate, etidronate, 
ibandronate, pamidronate, risedronate, tiludronate, and zoledronic acid. Approximately 30 
million prescriptions are written for bisphosphonates annually in the United States.8
In 2007, a randomized, double-blind, placebo-controlled study in nearly 4,000 patients with 
osteoporosis found that zoledronic acid significantly increased the incidence of serious atrial 
fibrillation (AF) (1.3% versus 0.5%, p<0.001).2 In addition, in a placebo-controlled study of 
6459 women with osteoporosis, a trend towards an increased incidence of serious AF was 
reported in association with alendronate (1.5% versus 1.0%, p=0.07).9 Since that time, a 
growing body of data has associated bisphosphonates with an increased risk of serious AF 
and overall AF. Data from case-controlled studies,10 cohort studies11 and meta-analyses12 
have also found significant associations between bisphosphonates and serious AF. In 
addition to these reports in patients receiving bisphosphonates for osteoporosis, studies have 
reported an association between bisphosphonates and AF, including serious AF, in patients 
with cancer receiving bisphosphonates for fracture prevention.13,14 Overall, a total of 12 
published studies have reported an association between bisphosphonates drugs and new 
onset and/or serious AF. However, conflicting data exist; some investigators have not found 
an association between bisphosphonates and AF;15,16 a lack of association between 
bisphosphonates and new onset and/or serious AF has been reported in 12 published studies.
Identification of the potential for bisphosphonates as possible causes of new onset AF is 
clinically important. AF causes symptoms including palpitations, shortness of breath, and 
dizziness, which negatively influence quality of life. Further, AF is associated with a 5-fold 
increase in the risk of stroke, which can result in permanent paralysis or death, and a 2-fold 
increase in the risk of cardiovascular death. Thus, AF induced by a class of drugs as widely 
prescribed bisphosphonates may have serious public health consequences. However, as 
mentioned above, not all studies have found an association between bisphosphonate drugs 
and AF, and questions remain regarding the proarrhythmic potential of these agents.
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In view of the disparate and conflicting data regarding the potential for bisphosphonates to 
provoke new-onset AF, we sought to test the hypotheses that zoledronic acid shortens atrial 
repolarization and influences P wave measures associated with an increased risk of AF.
Methods
This investigation consisted of three experiments: 1) Ex vivo zoledronic perfusion of isolated 
guinea pig hearts; 2) In vivo zoledronic dose response in guinea pigs, and 3) In vivo 
zoledronic administration to canines. This investigation conformed to the National Institute 
of Health’s Guide for the Care and Use of Laboratory Animals, and was approved by the 
Institutional Animal Care and Use Committee at Indiana University Purdue University 
Indianapolis.
Ex vivo zoledronic acid perfusion
Female Dunkin-Hartley retired breeder guinea pigs (approximately 2.5 years old; n=12) 
were anesthetized with pentobarbital 50 mg/kg and anticoagulated with heparin 500 IU 
administered intraperitoneally. Additional doses of sodium pentobarbital 10 mg/kg were 
administered as needed. The diaphragm was accessed and the thorax opened with a bilateral 
incision, exposing the heart, which was rapidly excised and quickly mounted on a 
Langendorff isolated perfused heart apparatus (IH-SR 5, Harvard Apparatus, Inc., Holliston, 
MA, USA), and immersed in a tissue bath filled with modified Krebs-Henseleit buffer, 
which consisted of: NaCL 118.5mM, KCl 4.7mM, MgSO4 1.2mM, NaHCO3 25.0mM, 
KH2PO4 1.2mM, CaCl2 1.8mM, and glucose 11.0mM. All reagents were obtained from 
Sigma Chemical Co. (St. Louis, MO, USA). The perfusate was equilibrated to 37° ± 0.5° C 
using a temperature control system (Thermostatic Circulator E103, Harvard Apparatus) and 
infused with 95% O2 & 5% CO2 at pH 7.4. The perfusate was maintained at constant 
temperature (37° C) and aortic pressure (60 mm Hg) throughout the study. A bipolar pacing 
electrode was placed on the right atrium. Hearts were paced at a basic cycle length of 250ms 
(240 bpm) at twice the diastolic pacing threshold using an HSE Stimulator PSM Type 676 
programmable stimulator (Hugo Sachs Elektronik, March-Hugstetten, Germany). One 
spring-loaded silver-silver chloride monophasic action potential (MAP) electrode was 
positioned on the left atrial epicardium. Following dissection and instrumentation, hearts 
were allowed to equilibrate for 10 minutes prior to initiation of the experimental protocol. 
Electrophysiological signals were amplified using a PLUGSYS module (MAP Module Type 
703, Hugo Sachs Elektronik) that allows for the simultaneous recording of up to 4 MAP 
signals.
Hearts were randomized to perfusion with zoledronic acid 0.07 mg/kg/L dissolved in Krebs-
Henseleit buffer (n=6) or Krebs-Henseleit buffer without zoledronic acid (control; n=6). 
After the 10-minute equilibration period, left atrial MAPs were recorded continuously for 20 
minutes. Data were recorded and acquired using the HSE-IsoHeart W data acquisition 
system (Hugo Sachs Elektronik-Harvard Apparatus, March-Hugstetten). Three beats from 
each set of recordings were selected for analysis and averaged for measurement of action 
potential duration (APD) prior to initiation of zoledronic acid perfusion and at baseline in 
the control group and every 5 minutes for 60 minutes following baseline measurements. 
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APDs were measured at 90% (APD90) and 30% repolarization (APD30) by an investigator 
(JET) who was blinded to the assigned treatment.
In vivo chronic zoledronic acid administration in guinea pigs
Female Dunkin-Hartley guinea pigs (n=32) were randomized to receive intraperitoneal 
injections every 2 weeks for 8 weeks in one of the following groups (n=8 each):
• Zoledronic acid 0.007 mg/kg (low dose)
• Zoledronic acid 0.07 mg/kg (medium dose; consistent, on a mg/kg basis, with the 
dose used in patients with cancer17)
• Zoledronic acid 0.7 mg/kg (high dose)
• Placebo (saline)
After 8 weeks, on the day after the last dose of zoledronic acid or placebo was administered, 
guinea pigs were anesthetized with pentobarbital 50 mg/kg and anticoagulated with heparin 
500 IU administered intraperitoneally. Excised hearts were mounted on a Langendorff 
isolated perfused heart apparatus as described above. Hearts were paced at a basic cycle 
length of 250ms (240 bpm) at twice the diastolic pacing threshold using an HSE Stimulator 
PSM Type 676 programmable stimulator (Hugo Sachs Elektronik, March-Hugstetten, 
Germany). One spring-loaded silver-silver chloride monophasic action potential (MAP) 
electrode was positioned on the left atrial epicardium. Following dissection and 
instrumentation, hearts were allowed to equilibrate for 10 minutes prior to initiation of the 
experimental protocol. Electrophysiological signals were amplified using a PLUGSYS 
module (MAP Module Type 703, Hugo Sachs Elektronik) that allows for the simultaneous 
recording of up to 4 MAP signals.
Following the 10-minute equilibration period, left atrial effective refractory period (ERP), 
was determined three times, 1 minute apart, in the following manner: Trains of 8 paced beats 
(S1) at a constant pacing cycle length (250 ms) were delivered, after which an extrastimulus 
(S2) was delivered starting at 100 ms following the last beat of the train, and decreased at 5 
ms decrements until the extrastimulus failed to generate an atrial depolarization. The longest 
S1–S2 interval that failed to generate a depolarization was defined as the ERP. APD90 and 
APD30 were determined by an investigator (JET) who was blinded to the assigned treatment 
and averaged from three consecutive beats at three times separated by one minute.
In vivo zoledronic acid administration to canines
Mature female beagle dogs (n=12) between 1–2 years of age (Marshall Farms, North Rose, 
NY) were randomized to receive intravenous zoledronic acid 0.067 mg/kg (n=6) every two 
weeks for 12 weeks or to an untreated control group (n=6);18 this dose is consistent with 
doses administered to patients for prevention of fractures associated with metastatic cancer. 
To perform drug administration, animals were sedated with medetomidine 0.15 mg, which 
was reversed with atipamezole 1 mg at the end of the infusion. To administer zoledronic 
acid, an over-the-needle catheter was inserted into the cephalic or saphenous vein; the site of 
injection was alternated for each dose. Zoledronic acid was administered in 40 mL normal 
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saline and infused over 15 minutes, consistent with the administration of the drug in clinical 
practice.
After 12-weeks of treatment, dogs were sedated with propofol 8 mg/kg. Three 12-lead 
electrocardiograms (paper speed 25 mm/s), separated by one minute, were obtained for 
analysis of P wave measurements known to be associated with risk of AF.19 P wave onset 
was determined as a positive deflection after the T wave preceding the QRS complex and 
deviating from the isoelectric line from the T wave to the P wave. The end of the P wave 
was defined as the return to isoelectric baseline immediately before the QRS complex.20 Up 
to 5 consecutive P waves were measured in each of the 12-leads. Leads in which P wave 
onset or termination could not be clearly discerned were not included for measurement. All 
P wave measurements were performed by the same investigator (HJ), who was blinded to 
the assigned treatments.
Maximum P wave duration was defined as the longest P wave measured from any of the 12 
ECG leads. P wave dispersion was defined as the difference between the maximum and 
minimum P wave duration across all 12 leads.20,21 P wave index was defined as the standard 
deviation of P wave duration across all 12 leads.19 Since in some studies bisphosphonates 
have not been shown to increase the incidence of overall AF, but rather only “serious” AF, 
we also measured PR interval to assess the possibility that bisphosphonates might have the 
potential to increase ventricular rates in AF by accelerating AV node conduction.
QRS duration and QT intervals were measured manually from lead II by an investigator 
(HJ) who was blinded to the assigned treatments. QT intervals were measured from the 
earliest QRS deflection to the end of the T wave, defined as the intersection of a tangent to 
the steepest slope of the last limb of the T wave and the baseline. QT intervals were 
corrected for heart rate using both the Bazett’s and Fridericia methods.
Statistical analysis
Analyses were performed using SPSS 17.0 (SPSS, Inc, Chicago, IL). Normality of 
continuous data was determined using the Kolmogorov-Smirnov test. Ex vivo perfusion 
study: % change in APD90 and APD30 from baseline over time was compared between the 
two groups using two-way repeated measures analysis of variance (ANOVA). In vivo dose 
response study: Mean ERP, APD90 and APD30 were compared across the four groups using 
ANOVA. Tukey’s Honest Significant Difference test was used post-hoc to analyze 
significant differences between the groups. In vivo canine ECG study: P wave indices in the 
two groups were compared using Student’s unpaired t-test. For all analyses, p< 0.05 was 
considered significant.
Results
Ex vivo zoledronic acid perfusion
The guinea pigs in the zoledronic acid and control groups were similar with respect to 
weight (978±47 vs 967±53g, p=0.71). The effect of acute zoledronic acid perfusion in 
isolated perfused guinea pig hearts is shown in Figure 1. Zoledronic acid perfusion resulted 
in a significant decrease in APD90 compared with hearts in the control group (Figure 1A). 
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The maximum decrease from baseline in APD90 in the zoledronic acid group was −23.2% ± 
−5.1%, compared with −2.1% ± −8.1% in the control group (Figure 2A, p<0.0001). 
Similarly, zoledronic acid perfusion resulted in a significant decrease in APD30 compared 
with hearts in the control group (Figure 1B). The maximum decrease from baseline in 
APD30 in the zoledronic acid group was −28.8% ± − 3.8% compared with − 2.1% ± −2.1% 
in the control group (Figure 2B, p<0.0001). There were no episodes of spontaneous AF.
In vivo zoledronic acid dose-response in guinea pigs
There was no significant difference in age of the guinea pigs between the low, medium, high 
dose and placebo groups (16.5±0.9, 16.0±1.4, 16.4±1.6, and 15.8±1.2 weeks, p=0.64). 
Similarly, there was no significant difference in weight of the guinea pigs between the low, 
medium, high dose and placebo groups (670±32, 650±39, 662±37, and 658±25g, p=0.34).
Dose-response effects of zoledronic acid on atrial ERP in isolated guinea pigs hearts are 
presented in Figure 3. Zoledronic acid provoked a significantly lower mean ERP compared 
with placebo across the dosing groups; post-hoc testing revealed significant differences 
between medium dose (p=0.004) and placebo and between high dose and placebo (p=0.02).
The effects of zoledronic acid administration on atrial APD30 are presented in Figure 4. 
Zoledronic acid elicited a significantly lower APD30 compared with control across the 
dosing groups. Post-hoc analysis revealed the following significant differences: high dose 
versus placebo (p=0.005); high dose versus low dose (p=0.0001); high dose versus medium 
dose (p=0.02). Zoledronic acid administration did not exert a significant effect on atrial 
APD90 (Figure 5). There were no episodes of spontaneous AF.
In vivo zoledronic acid administration in canines
The effects of zoledronic acid on ECG measures of atrial activity in beagle dogs are 
presented in Table 1. Mean P wave dispersion was significantly greater in the zoledronic 
acid group compared with that in the control group. There were no significant differences 
between the zoledronic acid and control groups in mean P wave index, maximum P wave 
interval duration, mean minimum P wave interval duration, or in mean PR interval. There 
were no significant differences between the zoledronic acid and control groups in mean QRS 
duration, Bazett’s- or Fridericia-corrected QT intervals, or heart rate (Table 1). There were 
no premature atrial or ventricular depolarizations on any of the ECGs, nor were there any 
episodes of spontaneous AF.
Discussion
Zoledronic acid influenced electrophysiological and electrocardiographic indices associated 
with an increased risk of AF. Acute zoledronic acid perfusion in isolated, perfused guinea 
pig hearts resulted in significant decreases in left atrial APD90 and APD30. Chronic 
intraperitoneal administration of zoledronic acid to guinea pigs significantly decreased left 
atrial ERP at medium and high doses, and significantly decreased left atrial APD30 at high 
doses. In addition, chronic intravenous administration of zoledronic acid to beagle canines 
resulted in a significant increase in P wave dispersion.
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Numerous clinical studies have implicated bisphosphonates as inducers of new-onset 
AF.2,9–14 In some reports, bisphosphonates were not associated with an overall increase in 
the incidence of new-onset AF, but were associated with an increased incidence of “serious” 
AF;2,9,12 definitions of “serious” AF were not provided. However, other investigators have 
associated bisphosphonates with contributing to an increase in the risk of all new-onset AF, 
not only “serious” AF.10–13 In contrast, some investigators have not found an association 
between bisphosphonate use and AF.14,15 Reasons for this disparity in findings are unclear, 
although the studies differ in design, bisphosphonate drug(s) investigated, patient inclusion, 
and data analysis. The influence of bisphosphonates on atrial electrophysiology or 
electrocardiographic measurements has not been described previously. The current results 
represent novel experimental data showing that zoledronic acid exerts electrophysiological 
and ECG effects known to be associated with an increased risk of AF.
The basis for our study was the fact that there is a substantial number of published clinical 
trials, case-controlled studies, cohort studies, and meta-analyses that report that 
bisphosphonates use is associated with an increased risk of AF. The potential association of 
bisphosphonates with new onset AF is controversial, and an equal number of published 
studies have not reported an association between bisphosphonates and new-onset AF. 
Nonetheless, the growing number of published studies that have found an association 
between bisphosphonate drugs and the occurrence of new onset AF led us to hypothesize 
that bisphosphonate drugs may affect atrial electrophysiological and electrocardiographic 
measures that are known to be associated with an increased risk of AF.
Reduced atrial ERP and shortening of the atrial APD are features associated with AF, and 
conditions that lead to decreased atrial APD and ERP are associated with an increased risk 
of AF.22 In the present study, acute zoledronic acid perfusion in isolated, perfused guinea 
pig hearts resulted in significant decreases in left atrial APD90 and APD30. Chronic 
administration of zoledronic acid to guinea pigs led to a significant decrease in atrial ERP at 
medium and high doses, and a significant decrease in APD30 in the high dose group. 
Chronic zoledronic acid administration to guinea pigs resulted in a trend towards a 
significant decrease in APD90 (p=0.08). Reasons for the greater change in APD30 (20.3% 
decrease at highest dose) compared with APD90 (14.4% decrease at highest dose) are not 
clear, but it is possible that bisphosphonates alter early-phase atrial repolarization to a 
greater degree than later phase. Zoledronic acid administration also resulted in significant 
reduction in atrial ERP at both the medium and higher doses, but only reduced atrial APD30 
at the highest dose. ERP most closely approximates APD70, rather than APD90;23 the fact 
that zoledronic acid significantly shortened ERP but not APD90 could also be due to a 
greater effect of zoledronic acid on early-phase atrial repolarization than later phase.
Mechanisms by which zoledronic acid decreases atrial ERP, APD30 and APD90 and 
increases P wave dispersion have not been studied. Bisphosphonates have been reported to 
provoke an inflammatory response,24 which may contribute to the development of AF. 
Bisphosphonates cause acute kidney injury in some patients,25 which could increase fluid 
volume and left atrial strain, resulting in AF. Although these mechanisms are possible, our 
ex vivo perfusion experiment suggests that zoledronic acid may exert direct atrial 
electrophysiological effects. Alendronate has been shown to induce oscillations in 
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intracellular calcium concentrations in atrial cells.26 In our investigation, zoledronic acid 
affected early phase atrial repolarization to a great degree than later phase, which could 
suggest an effect on Ikur and/or calcium current.27 The contribution of these and other 
potential mechanisms of bisphosphonates to the development of AF requires additional 
study. Future research should also investigate the propensity for bisphosphonates to induce 
AF in experimental models, and to determine whether there are differences among the 
available bisphosphonate drugs in their potential to induce AF and atrial 
electrophysiological changes that promote AF. In particular, in light of our findings 
indicating that direct perfusion of zoledronic acid to isolated guinea pig hearts alters atrial 
action potential duration, studies in single atrial myocytes to determine effects of 
bisphosphonates on specific ionic currents are desired.
The medium zoledronic acid dose selected for use in the in vivo guinea pig experiment and 
the zoledronic acid dose selected for use in the chronic in vivo canine experiment were 
similar, on a mg/kg basis, to the 4 mg dose recommended for patients for the management of 
hypercalcemia of malignancy, multiple myeloma and bone metastasis from solid tumors. 
The low and high zoledronic acid doses in the in vivo guinea pig experiment were 10-fold 
lower and higher, respectively. The zoledronic acid concentration perfused through the 
isolated guinea pig hearts was also selected to mimic the dose use for the above indications.
Specific P wave indices have been shown to be associated with an increased risk of AF. 
Maximum and minimum P wave duration have been shown to predict the development in 
AF in some studies.19,20 However, associations between P wave duration and AF have been 
inconsistent, and other studies have not found maximum or minimum P wave duration to be 
independent predictors of the development of AF,28 or have found P wave dispersion to be a 
better predictor of AF than P wave duration based on comparison of receiver operating 
characteristics curves.29 In this investigation, zoledronic did not significantly influence 
maximum or minimum P wave duration.
In comparison with P wave duration, P wave dispersion has more consistently been shown 
to be associated with development or perpetuation of AF. Increased P wave dispersion was 
shown to be independently associated with an increased risk of new onset AF in broad 
populations of patients,19 as well as in those with hypertension28 and chronic obstructive 
pulmonary disease.30 Increased P wave dispersion (but not maximum P wave duration) was 
independently associated with progression from paroxysmal to persistent AF.20 Increased P 
wave dispersion was also associated with recurrence of AF after conversion to sinus 
rhythm.21 Increases in postoperative P wave dispersion independently predict AF following 
coronary artery bypass graft (CABG) surgery.31 Finally, a reduction in P wave dispersion 
following cardiac resynchronization therapy was associated in a lower incidence of new-
onset AF in patients with heart failure.32 Overall, a large body of evidence suggests that P 
wave dispersion may promote the development and/or perpetuation of AF.
P wave index, defined as the standard deviation of P wave duration across all leads, has also 
been shown to be a strong predictor of the development of AF.19 Zoledronic acid increased 
P wave index by > 2-fold in the canines studied in this investigation (p=0.06). Zoledronic 
acid did not significantly influence PR interval, suggesting that these drugs may not affect 
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AV nodal conduction. Zoledronic acid had no significant effects on canine QRS duration, 
rate-corrected QT interval, or heart rate. Bonilla et al33 also reported no effects of a 
bisphosphonate (ibandronate) on QT interval up to 4 weeks post-dosing, compared to 
baseline values, in canines.
Limitations of these investigations warrant consideration. In the in vivo guinea pig 
experiment, zoledronic acid was administered via the intraperitoneal route. While zoledronic 
acid has been administered intraperitoneally by other investigators to other small animal 
species,34 the bioavailability of intraperitoneal zoledronic acid in those models and in the 
guinea pig is unknown. Therefore, while the medium zoledronic acid dose was selected to 
simulate therapeutic zoledronic acid doses administered to patients with cancer, it is 
unknown whether plasma zoledronic acid concentrations were similar to those achieved by 
the same mg/kg dose when administered intravenously to patients. The anesthetic agent used 
in the in vivo canine experiment was propofol, which has been shown to decrease P wave 
dispersion in patients receiving propofol anesthesia for surgery.35 However, we employed a 
control group in addition to the experimental group; both groups received propofol 
anesthesia at the same dose. In contrast to the in vivo guinea pig experiments, in which both 
atrial ERP and APD were measured, only atrial APD (but not ERP) was measured in the ex 
vivo guinea pig experiments. This was because the ex vivo guinea pig experiments were 
conducted first, to test the initial hypothesis that acute perfusion of zoledronic acid shortens 
atrial repolarization, and to determine whether the data would support further 
experimentation regarding the influence of zoledronic acid on atrial electrophysiology.
Conclusions
In vivo zoledronic acid administration in guinea pigs significantly reduces left atrial ERP at 
medium and high doses, and reduces left atrial APD30 at high doses. Chronic intravenous 
zoledronic acid therapy in canines significantly increases P wave dispersion. Direct ex vivo 
zoledronic acid perfusion significantly decreases left atrial APD90 and APD30 in isolated 
guinea pig hearts, suggesting that zoledronic acid may exert direct effects on atrial 
electrophysiology.
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Figure 1. 
Effects of perfusion of zoledronic acid on APD90 and APD30 in isolated perfused guinea pig 
hearts. Data presented as mean ± standard deviation
A. Effect on APD90
B. Effect on APD30
*p<0.05 compared to control at these time points
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Figure 2. 
Effects of perfusion of zoledronic acid on % change from baseline APD90 and APD30 in 
isolated perfused guinea pig hearts. Data presented as mean ± standard deviation
A. Effect on APD90
B. Effect on APD30
*p<0.05 compared to control at these time points
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Figure 3. 
Effects of chronic in vivo zoledronic acid administration on atrial effective refractory period 
(ERP) in guinea pig hearts. Data presented as mean ± standard deviation
*Analysis of variance p value comparing the four groups
¶Tukey’s posthoc p=0.004 Medium dose compared to placebo
§Tukey’s posthoc p=0.02 High dose compared to placebo
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Figure 4. 
Effects of chronic in vivo zoledronic acid administration on atrial action potential duration at 
30% repolarization (APD30). Data presented as mean ± standard deviation.
*Analysis of variance p value comparing the four groups
¶Tukey’s posthoc p=0.005 high dose compared to placebo
¶Tukey’s posthoc p<0.0001 high dose compared to low dose
¶Tukey’s posthoc p=0.02 high dose compared to medium dose
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Figure 5. 
Effects of chronic in vivo zoledronic acid administration on atrial action potential duration at 
90% repolarization (APD90). Data presented as mean ± standard deviation
*Analysis of variance p value comparing the four groups
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Table 1
Effect of zoledronic acid on P wave measurements associated with increased risk of atrial fibrillation in dogs. 
Data presented as mean ± standard deviation.
Zoledronic acid Control p
P wave dispersion (ms) 8 ± 4 3 ± 3 0.04
P wave index (ms) 42 ± 20 20 ± 15 0.06
Maximum P wave duration (ms) 39 ± 6 39 ± 11 0.97
Minimum P wave duration (ms) 31 ± 4 36 ± 9 0.29
PR interval (ms) 90 ± 16 91 ± 14 0.97
QRS duration (ms) 74 ± 10 67 ± 11 0.15
QTc* interval (ms) 462 ± 22 460 ± 20 0.77
QTF† interval (ms) 457 ± 18 454 ± 16 >0.99
RR interval (ms) 403 ± 44 405 ± 52 0.90
Heart rate (bpm) 151 ± 17 148 ± 19 0.64
*QTc interval = Bazett’s-corrected
†QTF interval = Fridericia-corrected
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